

Non-Small Cell Lung Cancer (NSCLC)

**A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]**

**Trial Status**  
Completed

**Trial Runs In**  
26 Countries

**Trial Identifier**  
NCT02367794 2014-003208-59  
GO29437

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This randomized, open-label study will evaluate the safety and efficacy of atezolizumab (MPDL3280A) in combination with carboplatin + paclitaxel or carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV squamous NSCLC.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02367794 2014-003208-59 GO29437**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---